Get the Stockscreener App
10.86
7.63%
0.77
Kura Oncology Inc stock is traded at $10.86, with a volume of 1.89M.
It is up +7.63% in the last 24 hours and down -3.38% over the past month.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
See More
Previous Close:
$10.09
Open:
$9.985
24h Volume:
1.89M
Relative Volume:
1.06
Market Cap:
$964.09M
Revenue:
$71.64M
Net Income/Loss:
$-294.57M
P/E Ratio:
-3.2437
EPS:
-3.348
Net Cash Flow:
$-84.46M
1W Performance:
+13.48%
1M Performance:
-3.38%
6M Performance:
+30.69%
1Y Performance:
+64.55%
1-Day Range:
$9.92
$11.02
1-Week Range:
$9.46
$11.31
52-Week Range:
$6.95
$12.49
Kura Oncology Inc Stock (KURA) Company Profile
Name
Kura Oncology Inc
Sector
Industry
Phone
(858) 500-8800
Address
4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA
Compare KURA vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
10.86 | 882.42M | 71.64M | -294.57M | -84.46M | -3.348 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-26 | Initiated | Lake Street | Buy |
| Sep-04-25 | Initiated | Guggenheim | Neutral |
| Feb-06-25 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-14-24 | Downgrade | Stifel | Buy → Hold |
| Dec-22-23 | Initiated | Mizuho | Buy |
| Aug-11-23 | Initiated | BofA Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Perform |
| May-17-23 | Initiated | BTIG Research | Buy |
| Jan-31-23 | Initiated | Stifel | Buy |
| Jul-12-22 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-15-22 | Initiated | Jefferies | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-07-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| Nov-05-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Initiated | Credit Suisse | Outperform |
| May-05-20 | Initiated | Barclays | Overweight |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| Nov-09-18 | Initiated | Piper Jaffray | Overweight |
| Aug-01-18 | Initiated | H.C. Wainwright | Buy |
| Oct-13-16 | Resumed | Leerink Partners | Outperform |
| Jan-22-16 | Initiated | JMP Securities | Mkt Outperform |
| Dec-30-15 | Initiated | Oppenheimer | Outperform |
| Dec-16-15 | Initiated | Citigroup | Buy |
View All
Kura Oncology Inc Stock (KURA) Latest News
Kura Oncology (KURA) investors report up to 9.7% beneficial ownership stakes - Stock Titan
Kura Oncology (NASDAQ:KURA) Stock Price Up 8% on Analyst Upgrade - MarketBeat
A Quick Look at Today's Ratings for Kura Oncology(KURA.US), With a Forecast Between $23 to $40 - Moomoo
Kura Oncology FY2029 EPS Cut by Brookline Capital Markets - MarketBeat
A Quick Look at Today's Ratings for Kura Oncology(KURA.US), With a Forecast Between $28 to $40 - Moomoo
BofA Securities Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $31 - Moomoo
Kura Oncology, Inc. Stock 12‑Month Price Target Raised to $32, Implies 222% Upside - TradingView
Kura Oncology (NASDAQ:KURA) Shares Gap Up After Strong Earnings - MarketBeat
KURA Maintained by Wedbush -- Price Target Raised to $38 - GuruFocus
Kura Oncology (NASDAQ:KURA) Price Target Raised to $38.00 at Wedbush - MarketBeat
Wedbush Adjusts Price Target on Kura Oncology to $38 From $36, Keeps Outperform Rating - marketscreener.com
Kura Oncology (NASDAQ:KURA): What Does the Latest Update Mean for Clinical Evidence? - Kalkine Media
Kura Oncology, Inc. Stock 12‑Month Price Target Raised to $31.83, Implies 220% Upside - tradingview.com
Kura Oncology (KURA) Q2 2026 Results Highlight Valuation Challen - GuruFocus
Kura Oncology Q2 2026 Earnings Call Transcript - MarketBeat
Kura Oncology, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Kura Oncology Q2 EPS $(0.77) beats estimate, sales miss - scanx.trade
Kura Oncology Q2 Earnings Call Highlights - MarketBeat
Earnings call transcript: Kura Oncology tops Q2 2026 estimates as launch gains - Investing.com
Kura Oncology (NASDAQ:KURA) Issues Earnings Results - MarketBeat
Kura Oncology (KURA) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Kura Oncology, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Kura Oncology Inc (KURA) Reports Q2 Revenue of $20.9M with Net L - GuruFocus
Kura Oncology Q2 Diluted Loss Widens, Revenue Rises - marketscreener.com
Kura Oncology: Q2 Earnings Snapshot - KTVB
Earnings Flash (KURA) Kura Oncology Posts Q2 Loss Per Share $0.77, vs. FactSet Est of Loss $0.88 - marketscreener.com
KURA ONCOLOGY ($KURA) Releases Q2 2026 Earnings - quiverquant.com
Q2 2026 Kura Oncology, Inc. Earnings Call Transcript - GuruFocus
Kura Oncology (KURA) grows revenue to $39.1M but widens net loss - Stock Titan
Kura Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Kura Oncology Q2 product revenue rises 57% on KOMZIFTI uptake - TradingView
Kura Oncology Reports Second Quarter 2026 Financial Results - The Manila Times
Earnings Flash (KURA) Kura Oncology, Inc. Reports Q2 Revenue $20.9M, vs. FactSet Est of $20.2M - marketscreener.com
BRIEF-Kura Oncology Q2 Operating Expenses USD 93.884 Million - TradingView
Kura Oncology, Inc. expected to post a loss of 88 cents a shareEarnings Preview - TradingView
Kura Oncology (KURA) Eps Diluted (TTM) - Zacks Investment Research
Kura Oncology (KURA) Advances Menin Inhibitor Research Amid Mixed Market Signals - GuruFocus
Kura Oncology highlights ziftomenib preclinical activity, menin binding profile in Blood publication - Bitget
Kura Oncology publishes preclinical data on ziftomenib in Blood By Investing.com - Investing.com South Africa
Kura Oncology publishes preclinical data on ziftomenib in Blood - Investing.com
Kura Oncology publishes study highlighting zift... - Pluang
Kura Oncology Announces Blood Publication Detailing Discovery, Preclinical Characterization and Resistance Profile of Ziftomenib - Quiver Quantitative
Kura Oncology Announces Publication in Blood Highlighting Ziftomenib’s Differentiated Binding Profile and Preclinical Activity - The Manila Times
Kura Oncology Announces Publication in Blood Highlighting - GlobeNewswire
Hennion & Walsh Asset Management Inc. Grows Stake in Kura Oncology, Inc. $KURA - MarketBeat
Dimensional Fund Advisors LP Increases Holdings in Kura Oncology, Inc. $KURA - MarketBeat
Sei Investments Co. Boosts Holdings in Kura Oncology, Inc. $KURA - MarketBeat
Kura Oncology Inc (KURA) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Kura Oncology, Inc. (KURA) stock price, news, quote and history - Yahoo Finance Australia
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Kura Oncology, Inc. (KURA) Stock Analysis: Exploring a 235.85% Potential Upside in the Biotechnology Sector - directorstalkinterviews.com
Kura Oncology Inc Stock (KURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):